For many Fabry disease patients, the path to diagnosis is long - not because answers don't exist, but because the genetic evidence needed to reach them has been scattered, incomplete, or missing from the databases clinicians rely on.
When the Evidence Isn't There, Families Wait
Fabry disease is a rare, X-linked lysosomal storage disorder caused by a deficiency of alpha-galactosidase A, encoded by the GLA gene. Because its symptoms - pain, fatigue, kidney dysfunction, cardiac involvement - can overlap with more common conditions, diagnosis is frequently delayed.
When a genetic test returns a variant of uncertain significance - not clearly pathogenic, not clearly benign - families wait. Sometimes for months. Sometimes longer. In a disease where earlier treatment can slow progression, that wait has real consequences.
The problem is not a lack of scientific knowledge. It is that the evidence supporting variant interpretation has been incomplete, inconsistently curated, and difficult to act on at the point of clinical decision-making.
Closing the GLA Evidence Gap
Through a strategic collaboration with Amicus Therapeutics, Genomenon systematically reviewed the published biomedical literature to identify, assess, and classify variants in the GLA gene, building an evidence base that clinicians can use when interpreting genetic test results.
More than 1,300 GLA variants were submitted to ClinVar, with over 1,000 classified as pathogenic or likely pathogenic. More than half were not previously represented in the database.
That evidence also supported a meaningful regulatory outcome: 15 additional GLA variants were added to the FDA label, meaning some patients who were previously excluded could now be considered for treatment access.
For every clinician who encounters one of those variants today, there is now evidence where there was none before.
What the Evidence Shows Over Time
At ACMG 2026, Genomenon presented a poster, “Tracking How Fabry Disease Evidence Evolves Over Time.” The poster examined how GLA variant classifications changed between 2023 and 2025 and what those shifts reveal about pathogenicity assessment in Fabry disease.
The poster was recognized as a top-rated abstract at ACMG 2026.
For clinicians managing patients with GLA variants, that kind of longitudinal view matters - because a classification that was uncertain two years ago may have the evidence to support a clinical decision today.
What This Means for Patients
For patients and families, every newly classified variant means one less uncertain answer. It means fewer families stuck in diagnostic limbo, fewer delays in care, and a better chance that the right treatment decisions can happen earlier.
When evidence becomes accessible and usable, a variant that once created uncertainty can help confirm a diagnosis, support treatment eligibility, and give clinicians greater confidence in the decisions they make.
The evidence was always in the literature. But until it is systematically found, evaluated, and connected to clinical interpretation, many patients cannot fully benefit from it.
Search your GLA variant in Mastermind → Genomenon.com
